2023 ESMO肾癌精粹解读  

The interpretation and review of renal carcinoma,2023 EMSO

作　　者：盛锡楠[1] 鄢谢桥 刘振华[2] 郭军[1] Sheng Xinan;Yan Xieqiao;Liu Zhenhua;Guo Jun(Department of Genitourinary Oncology,Peking University Cancer Hospital,Beijing 100142,China;Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]北京大学肿瘤医院泌尿肿瘤内科,北京100142 [2]四川大学华西医院泌尿外科,成都610041

出　　处：《中华泌尿外科杂志》2023年第12期893-896,共4页Chinese Journal of Urology

摘　　要：2023年欧洲肿瘤内科学会(ESMO)年会报道了肾癌领域临床治疗、生物标志物以及新药/新机制探索等各方面研究进展,其中包括我国第一个靶免联合方案的Ⅲ期临床研究,缺氧诱导因子2α、抗体药物偶联物、双特异性抗体和抗体药物偶联物的临床研究,外周血、组织聚糖图谱和组织蛋白相关的生物标志物。本文对其中重要研究进行解读和点评,以期为临床治疗决策提供帮助。The 2023 European Society for Medical Oncology(ESMO)annual meeting reported on the research progress in the field of clinical treatment,biomarkers,and exploration of new drugs/mechanisms for renal carcinoma,which included the first phase Ⅲ trial of vascular endothelial growth factor receptor-tyrosine kinase inhibitor/immune checkpoint inhibitor(VEGFR-TKI/ICI)combination in Chinese population,trials of hypoxia inducible factor-2α(hif-2α)inhibitor,programmed cell death-Ligand 1/cytotoxic T-lymphocyte-associated antigen 4(PD-1/CTLA-4)bispecific monoclonal antibody and antibodydrug conjugate,biomarkers of peripheral blood,tissue glycan profiling and tissue protein.This article interprets and reviews important studies to help clinical treatment decisions.

关 键 词：肾癌 研究进展 临床治疗决策 

分 类 号：R737.11[医药卫生—肿瘤]